Schrödinger's growth was soft in the third quarter, and the company's losses continue to grow due to investments in internal programs. Operating expenses are expected to level out going forward, ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s ...
Schrödinger's stock has fallen 64% since January 2023, driven by missed revenue and EPS targets, despite ongoing AI-powered drug discovery efforts. Financial health remains stable with a current ratio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results